The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer

International Journal of Molecular Sciences

Shiu-Jau Chen¹  Shao-Cheng Wang²  Yuan-Chuan Chen³ 

[1] Department of Neurosurgery, Mackay Memorial Hospital, Taipei 104217, Taiwan;Department of Psychiatric, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 33004, Taiwan;Jenteh Junior College of Medicine, Nursing and Management, Hou-Loung Town, Miaoli County 35664, Taiwan;

关键词: colorectal cancer;    lung cancer;    pancreatic cancer;    immunotherapy;    immune checkpoint;    monoclonal antibody;   

DOI  :  10.3390/ijms222312836

来源: DOAJ

【 摘 要 】

Immunotherapy is a novel anti-cancer method which employs a different mechanism to conventional treatment. It has become a significant strategy because it provides a better or an alternative option for cancer patients. Recently, immunotherapy has been increasingly approved for the treatment of cancer; however, it has various limitations; for instance, it is only suitable for specific patients, the response rate is still low in most cases, etc. Colorectal cancer, lung cancer and pancreatic cancer are known as three major death-causing cancers in most countries. In this review, we discuss immunotherapeutic treatment for these three cancers, and consider the option, prospects and limitations of immunotherapy. The development of immunotherapy should focus on the discovery of biomarkers to screen suitable patients, new targets on tumors, neoadjuvant immunotherapy and the combination of immunotherapy with conventional therapeutic methods. We can expect that immunotherapy potentially will develop as one of the best therapies for patients with advanced cancer or poor responses to traditional methods.

【 授权许可】

Unknown